Taysha Gene Therapies, Inc. (TSHA) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 2 funds adding, and 2 funds trimming or exiting versus the previous quarter. Latest close $3.99 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Avoro Capital Advisors · RA Capital Management · RTW Investments — 6 tracked funds hold TSHA. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
ACADIA PHARMACEUTICALS INC (ACAD) · FAETH THERAPEUTICS INC (FTH) · Kodiak Sciences Inc. (KOD) · KYMERA THERAPEUTICS INC (KYMR) · MADRIGAL PHARMACEUTICALS INC (MDGL) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Avoro Capital Advisors | 1.46% | 23,888,888 | ADDED (+10.1%) Q3 filed Nov 16 |
| RA Capital Management | 1.39% | 23,555,648 | HELD Q3 filed Nov 16 |
| RTW Investments | 0.79% | 13,560,258 | TRIMMED (-0.9%) Q3 filed Nov 16 |
| OrbiMed Advisors | 0.25% | 2,000,000 | NEW Q3 filed Nov 16 |
| Baker Bros. Advisors | 0.14% | 4,004,756 | HELD Q3 filed Nov 16 |
| Polen Capital Management | 0.03% | 489,219 | ADDED (+53.0%) Q3 filed Nov 13 |
| Deerfield Management | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -39.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 209 of 8,857 filers |
| Long-only filers among them | 209 |
| Change vs 2026 Q1 | +22 net · 205 entered · 183 exited |
| Shares reported, all filers | 299,577,796 |
| Reported value, all filers | $2.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Revenue · FY2025 | $9.8M |
| Net income · FY2025 | $-109.0M |
| Total assets · FY2025 | $343.3M |
| Shares outstanding | 325,833,545 |
| Market cap (at latest close) | $1.3B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 11, 2026.
| Shares short · Oct 15, 2026 | 51,249,292 |
| Share of shares outstanding | 15.73% |
| Days to cover | 11.56 |
Shares short at recent settlements — Jul 31, 2026: 46.7M · Aug 14, 2026: 46.7M · Aug 31, 2026: 46.8M · Sep 15, 2026: 51.4M · Sep 30, 2026: 55.0M · Oct 15, 2026: 51.2M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 11, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 11, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jul 10, 2026 | Nagendran Sukumar | Officer | 200,000 | $1.3M | Jul 10, 2026 | SEC filing |
| Apr 10, 2026 | Nagendran Sukumar | Officer | 200,000 | $926.0K | Apr 10, 2026 | SEC filing |
| Feb 27, 2026 | Rumana Haque-Ahmed | Officer | 2,405 | $11.0K | Feb 27, 2026 | SEC filing |
| Feb 4, 2026 | Rumana Haque-Ahmed | Officer | 697 | $3.3K | Feb 4, 2026 | SEC filing |
| Feb 4, 2026 | Sean McAuliffe | Affiliate - Chief Business Officer | 914 | $4.3K | Feb 4, 2026 | SEC filing |
| Feb 4, 2026 | Fred Porter | Affiliate-Chief of Staff & Tech.Op.Officer | 889 | $4.2K | Feb 4, 2026 | SEC filing |
| Feb 4, 2026 | Emily McGinnis | Affiliate-Chief Pat. Adv. & Ext. Aff. Off. | 901 | $4.3K | Feb 4, 2026 | SEC filing |
| Feb 4, 2026 | Kamran Alam | Officer | 1,655 | $7.8K | Feb 4, 2026 | SEC filing |
| Jan 23, 2026 | Rumana Haque-Ahmed | Officer | 30,052 | $153.0K | Jan 23, 2026 | SEC filing |
| Jan 23, 2026 | Sean McAuliffe | Affiliate - Chief Business Officer | 46,064 | $234.5K | Jan 23, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jun 3, 2025 | SCHEDULE 13D/A | +43.4% (close Jun 4, 2025 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jun 4, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | RA Capital Management, L.P. | SC 13G/A | 32,886,242 | 9.9% | Jun 30, 2026 | SEC filing |
| Aug 13, 2026 | Morgan Stanley | SC 13G/A | 16,244,339 | 5.1% | Jun 30, 2026 | SEC filing |
| May 15, 2026 | RTW Investments, LP | SC 13G/A | 20,689,084 | 7.0% | Mar 31, 2026 | SEC filing |
| May 15, 2026 | Vestal Point Capital, LP | SC 13G/A | 18,000,000 | 6.3% | Mar 31, 2026 | SEC filing |
| Feb 17, 2026 | RTW Investments, LP | SC 13G/A | 23,407,133 | 8.3% | Dec 31, 2025 | SEC filing |
| Feb 17, 2026 | Vestal Point Capital, LP | SC 13G | 13,750,000 | 5.0% | Dec 31, 2025 | SEC filing |
| Feb 5, 2026 | FMR LLC | SC 13G/A | 13,528,365.87 | 4.9% | Dec 31, 2025 | SEC filing |
| Jan 21, 2026 | BlackRock, Inc. | SC 13G/A | 17,852,291 | 6.5% | Dec 31, 2025 | SEC filing |
| Nov 14, 2025 | RA Capital Management, L.P. | SC 13G/A | 27,662,481 | 9.9% | Sep 30, 2025 | SEC filing |
| Nov 14, 2025 | Octagon Capital Advisors LP | SC 13G/A | 9,067,500 | 3.3% | Sep 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 17 Lobbying Disclosure Act filings named this company as client, 2020–2026; most common issues: Health Issues (13), Medicare/Medicaid (12).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Distress Risk (Altman Z″) — Z″-Score: -0.53 · Working capital / assets: 0.87 · Retained earnings / assets: -2.07 · EBIT / assets: -0.32 · Equity / liabilities: 2.56
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2023 Q3, ranked #9 of 50.
Also held by the tracked funds that hold TSHA — ranked by lift, the co-holding pattern described in Methodology: ACADIA PHARMACEUTICALS INC (ACAD) · FAETH THERAPEUTICS INC (FTH) · Kodiak Sciences Inc. (KOD) · KYMERA THERAPEUTICS INC (KYMR) · MADRIGAL PHARMACEUTICALS INC (MDGL) · PTC THERAPEUTICS, INC. (PTCT) · UroGen Pharma Ltd. (URGN) · Aktis Oncology, Inc. (AKTS).
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 11, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jun 25, 2026 | 1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
ACADIA PHARMACEUTICALS INC (ACAD) · Track Record: how the signals scored · Practice timing on TSHA
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.